VIDEO: PARP inhibitors ‘changed the way we think’ about ovarian cancer treatment

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

It's really changed the way we think about treatment, not just sort of standard therapy, but upfront treatment for patients with ovarian cancer. One of the things we do know is that PARP inhibitors are not the holy grail, so many patients will develop resistance to PARP inhibitors. One of the things that additional studies have kind of shed light on is the fact that once resistance occurs to PARP inhibitor, we can actually go after other neural repair pathways that will synergize with PARP inhibitors to cause death of these cancer cells, and so one of the areas right now that people are really focused on is what other drugs can we combine with PARP inhibitors to make the cancer cells susceptible and die? And there's a lot of excitement around combinations with ATR inhibitors, or pol-theta inhibitors, league one inhibitors, all these are far into clinical development, and many of them are showing really exciting results in combination. I recently saw preclinical data that suggests that even when you combine PARP inhibitors and some of these other DNA repair inhibitors, that now they may become susceptible to immunotherapy. So this could help us bring immunotherapy back into the fold, which sadly, on their own, have not really shown much activity in ovarian cancer, but in the right combinations, might actually be quite helpful.